Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of Jankistomig

Trial Profile

Clinical study of Jankistomig

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Jankistomig (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Jun 2025 New trial record
  • 18 Jun 2025 According to LOTTE BIOLOGICS media release, announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma. This manufacturing collaboration marks a significant milestone in our commitment to advancing Jankistomig with speed and precision. Partnering with Lotte's proven biomanufacturing capabilities enhances our operational readiness and supports our rapid path to IND submission and clinical trial initiation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top